Cargando…

Risk factors associated with prolonged viral clearance in patients with a refractory course of COVID-19: a retrospective study

BACKGROUND: This study aimed to characterize a cohort of patients with a refractory course of COVID-19, and to investigate factors associated with the duration of viral clearance (DoVC). MATERIALS & METHODS: A total of 65 patients with refractory COVID-19 were retrospectively enrolled from Huosh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Weitao, Huang, Shujie, Wang, Dongya, Zha, Lulu, Xu, Wei, Qiao, Guibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621710/
https://www.ncbi.nlm.nih.gov/pubmed/34900440
http://dx.doi.org/10.7717/peerj.12535
Descripción
Sumario:BACKGROUND: This study aimed to characterize a cohort of patients with a refractory course of COVID-19, and to investigate factors associated with the duration of viral clearance (DoVC). MATERIALS & METHODS: A total of 65 patients with refractory COVID-19 were retrospectively enrolled from Huoshenshan Hospital. Univariate analysis and multivariate analysis were performed to examine the potential association between clinicopathologic characteristics and the DoVC. RESULTS: The median DoVC in the overall study cohort was 48 days (ranged from 21 to 104 days). Multivariate analysis indicated that fever at illness onset (Hazard ratio (HR) = 4.897, 95% CI [1.809–13.260], p = 0.002), serum level of aspartate aminotransferase (AST) > 21.8 IU/L (HR = 3.010, 95% CI [1.195–7.578], p = 0.019), and titer of SARS-CoV-2 IgG > 142.09 AU/ml (HR = 3.061, 95% CI [1.263–7.415], p = 0.013) were the three independent risk factors associated with delayed viral clearance. CONCLUSION: The current study suggested that clinical characteristics such as fever at illness onset, a high serum level of AST or SARS-CoV-2 IgG were associated with delayed viral clearance. Patients with these characteristics might need a more individualized treatment strategy to accelerate their recovery from the refractory COVID-19.